After verification, we found that GLXBBX alleviated hyperlipidemia induced by P407 by activating LPL activity, and GLXBBX inhibited early hepatic steatosis by antagonizing the mRNA overexpression of SCD1, blocking hepatic TG synthesis. Here, SCD is linked to fatty liver disease.